Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Short interest in Eli Lilly and Co (NYSE:LLY) decreased during the last reporting period, falling from 7.02M to 6.43M. This put 0.81% of the company's publicly available shares short. Short ...